ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
아베마시클립 시장 규모는 최근 급속히 확대하고 있습니다. 2024년 14억 2,000만 달러에서 2025년에는 16억 달러로 CAGR 12.5%로 확대합니다. CDK4 및 CDK6 억제제의 임상시험 성공률 증가, 암 분야 표적치료제 도입 확대, 조기 유방암의 보조요법 사용 증가, 동반진단 약물의 가용성 확대, 환자 옹호 및 인식 개선 캠페인 증가 등이 이 기간 중 성장을 촉진했습니다.
아베마시클립 시장 규모는 향후 수년간 급격한 성장이 예상됩니다. 2029년에는 CAGR 12.2%로 25억 4,000만 달러로 성장할 것입니다. 예측 기간 중의 성장에는 면역항암제와의 병용요법 승인 증가, 신규 제제 및 차세대 CDK 억제제 파이프라인 증가, 정부 프로그램을 통한 암 치료 접근성 확대, 바이오마커에 기반한 환자 선택 증가, 우수한 전체 생존율에 따른 치료 기간 연장 등이 기여하고 있습니다. 예측 기간의 주요 동향으로는 표적치료제 적용의 발전, 맞춤의료의 통합, 신흥 시장 진출, 제형 및 전달방식의 혁신, 임상시험 적용의 발전 등을 꼽을 수 있습니다.
아베마시클립은 사이클린 의존성 키나아제 4와 6(CDK4/6)을 선택적으로 표적으로 하는 경구용 저분자 억제제입니다. 세포주기를 조절하는 이들 효소를 억제함으로써 암세포의 증식을 억제합니다. 아베마시클립은 호르몬 수용체 양성, HER2 음성 유방암의 초기 및 진행성 유방암 치료에 주로 내분비 요법과 병용하여 사용됩니다.
아베마시클립의 주요 유형은 정제, 캡슐제, 기타가 있습니다. 정제는 유방암 환자의 표적 치료를 목적으로 하는 경구 투여 제제입니다. 적응증은 진행성 및 전이성 유방암, 조기 유방암 등입니다. 이 제품들은 온라인 및 오프라인 채널을 통해 유통되며, 병원, 암 치료 센터 등 최종사용자들이 사용하고 있습니다.
2025년 봄, 미국의 갑작스러운 관세 인상과 이에 따른 무역 마찰은 제약회사에 심각한 영향을 미치고 있습니다. 이익이 적은 제네릭 의약품 제조업체는 특히 취약하며, 일부 기업은 수익성이 낮은 의약품의 생산을 축소하기도 합니다. 생명공학 기업은 관세와 관련된 특수 시약의 부족으로 인해 임상시험이 지연되고 있습니다. 이에 업계는 인도와 유럽에서 원료의약품 생산을 확대하고, 재고 비축을 늘리며, 필수의약품의 무역 면제를 요구하고 있습니다.
이 조사 보고서는 아베마시클립 산업 세계 시장 규모, 지역별 점유율, 아베마시클립 시장 점유율을 가진 경쟁사, 상세한 아베마시클립 시장 부문, 시장 동향, 비즈니스 기회 등 아베마시클립 시장 통계를 제공하며, 아베마시클립 산업에서 성공하기 위해 필요한 데이터를 제공합니다. The Business Research Company의 새로운 보고서 시리즈 중 하나입니다. 이 아베마시클립 시장 조사 보고서는 업계의 현재와 미래 시나리오를 자세히 분석하여 필요한 모든 것을 완벽한 관점으로 제공합니다.
유방암 발병률 증가는 향후 수년간 아베마시클립 시장의 성장을 가속할 것으로 예측됩니다. 유방암은 유선 조직에 발생하는 악성 종양으로 주로 유관과 소엽을 침범하며, 치료하지 않으면 신체의 다른 부위로 전이될 수 있습니다. 유방암 발병률이 증가하고 있는 주요 이유는 발견 및 검진 기술의 향상으로 인해 과거에는 발견되지 않았을 수도 있는 유방암을 더 많이 진단할 수 있게 되었기 때문입니다. 아베마시클립은 종양세포의 증식을 촉진하는 특정 효소를 억제하여 유방암의 진행을 지연시키고 환자의 예후를 개선합니다. 예를 들어 2025년 2월 프랑스에 본부를 둔 정부 간 기구인 국제암연구소(IARC)는 2022년 전 세계에서 약 230만 명의 여성이 유방암 진단을 받고 67만 명이 사망할 것이라고 보고했습니다. 예측에 따르면 2050년까지 매년 320만 명이 발병하고 110만 명이 사망할 것으로 예측됩니다. 그 결과, 유방암 유병률 증가가 아베마시클립 시장 확대를 주도하고 있습니다.
아베마시클립 시장에서 활동하는 기업은 치료 효과를 높이고, 고위험군 조기 유방암 환자의 재발을 억제하며, HR+, HER2- 유방암의 다양한 병기에 걸쳐 치료 옵션을 확대하기 위해 내분비 요법과의 병용요법 등 혁신에 집중하고 있습니다. 내분비요법과의 병용요법에서는 호르몬 차단요법과 병행하여 아베마시클립을 사용함으로써 HR+ 유방암 세포의 증식을 보다 효과적으로 지연시키거나 멈추게 합니다. 예를 들어 2022년 11월 미국 제약회사 일라이 릴리(Eli Lilly and Company)는 조기 유방암 치료제로 라미벤을 인도에서 출시했습니다. 이 치료법은 호르몬 수용체 양성(HR+), HER2 음성, 림프절 전이 양성으로 재발 위험이 높은 환자를 타겟으로 합니다. 라미벤은 내분비 요법과 함께 사용하면 치료 효과를 높이고 암의 재발 가능성을 낮출 수 있습니다. 이번 출시로 인도의 고위험군 유방암 환자들에게 첨단 표적치료제에 대한 접근성이 크게 확대될 것으로 기대됩니다. 아베마시클립과 내분비요법의 병용투여를 통해 환자의 예후를 개선하고 보다 효과적인 치료 전략을 제공하고자 합니다.
2022년 2월, 미국 바이오 제약회사 벨은 여성 건강과 종양에 초점을 맞춘 표적 치료제의 개발 및 상용화를 위해 일라이 릴리 앤 컴퍼니와 제휴를 맺었습니다. 이번 제휴는 AR+ER+HER2 전이성 유방암 2차 치료에서 Veru의 enobosarm과 Eli Lilly의 Verzenio(성분명: 아베마시클립)의 병용투여의 안전성과 유효성을 평가하기 위한 것입니다. 아베마시클립을 개발 및 공급하는 일라이 릴리는 진행성 및 조기 유방암에 대한 보다 종합적인 치료 옵션을 제공하기 위해 노력하고 있습니다.
아베마시클립 시장의 주요 업체는 일라이 릴리 앤 컴퍼니(Eli Lilly & Co.)입니다.
2024년 아베마시클립 시장에서 가장 규모가 큰 지역은 북미입니다. 아시아태평양은 예측 기간 중 가장 빠르게 성장할 것으로 예측됩니다. 아베마시클립 보고서의 대상 지역은 아시아태평양, 서유럽, 중동 및 동유럽, 북미, 남미, 중동 및 아프리카입니다.
아베마시클립 시장 보고서의 대상 국가는 호주, 브라질, 중국, 중국, 프랑스, 독일, 인도, 인도, 인도네시아, 일본, 러시아, 한국, 영국, 미국, 캐나다, 이탈리아, 스페인입니다.
아베마시클립 시장은 용량 변형, 임상시험용 제제, 조합 키트 또는 요법 판매로 구성됩니다. 이 시장의 가치는 '팩토리 게이트' 가치, 즉 상품의 제조자 또는 공급자가 다른 사업체(다운스트림 제조업체, 도매업체, 유통업체, 소매업체 포함) 또는 직접 최종 고객에 의해 판매된 상품의 가치입니다. 이 시장에서 상품의 가치에는 상품을 만든 사람이 판매하는 관련 서비스도 포함됩니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 아베마시클립 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 아베마시클립 시장 : 성장률 분석
세계의 아베마시클립 시장 실적 : 규모와 성장, 2019-2024
세계의 아베마시클립 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 아베마시클립 : TAM(Total Addressable Market)
제6장 시장 세분화
세계의 아베마시클립 시장 : 제품 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
태블릿
캡슐
기타 제품 유형
세계의 아베마시클립 시장 : 적응증별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
진행성 또는 전이성 유방암
조기 유방암
기타 적응증
세계의 아베마시클립 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
온라인
오프라인
세계의 아베마시클립 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
암치료 센터
기타 최종사용자
세계의 아베마시클립 시장 : 서브 세분화 태블릿, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
표준 정제
서방형 정제
세계의 아베마시클립 시장 : 서브 세분화 캡슐, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
하드 젤라틴 캡슐
소프트 젤라틴 캡슐
세계의 아베마시클립 시장 : 서브 세분화 기타 제품 유형, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
경구 현탁액
주사제
외용제
제7장 지역별·국가별 분석
세계의 아베마시클립 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 아베마시클립 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
아베마시클립 시장 : 경쟁 구도
아베마시클립 시장 : 기업 개요
Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
제31장 세계의 시장 경쟁 벤치마킹과 대시보드
제32장 주요 합병과 인수
제33장 최근 시장 동향
제34장 시장의 잠재력이 높은 국가, 부문, 전략
아베마시클립 시장 2029 : 새로운 기회를 제공하는 국가
아베마시클립 시장 2029 : 새로운 기회를 제공하는 부문
아베마시클립 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁사 전략
제35장 부록
KSA
영문 목차
영문목차
Abemaciclib is an oral small molecule inhibitor that selectively targets cyclin-dependent kinases 4 and 6 (CDK4/6). By blocking these enzymes, which regulate the cell cycle, it prevents cancer cell proliferation. Abemaciclib is primarily used in combination with endocrine therapy to treat hormone receptor-positive, HER2-negative breast cancer in both early and advanced stages.
The primary types of abemaciclib are tablets, capsules, and others. Tablets are orally administered formulations designed for targeted treatment of breast cancer patients. Indications include advanced or metastatic breast cancer, early breast cancer, and others. These products are distributed through online and offline channels and are used by end users such as hospitals, cancer treatment centers, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The abemaciclib market research report is one of a series of new reports from The Business Research Company that provides abemaciclib market statistics, including the abemaciclib industry global market size, regional shares, competitors with the abemaciclib market share, detailed abemaciclib market segments, market trends, and opportunities, and any further data you may need to thrive in the abemaciclib industry. This abemaciclib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The abemaciclib market size has grown rapidly in recent years. It will grow from $1.42 billion in 2024 to $1.60 billion in 2025 at a compound annual growth rate (CAGR) of 12.5%. The growth during the historic period was driven by increasing clinical trial success rates for CDK4 and CDK6 inhibitors, growing adoption of targeted therapies in oncology, rising use of adjuvant therapy in early breast cancer, expanded availability of companion diagnostics, and increased patient advocacy and awareness campaigns.
The abemaciclib market size is expected to see rapid growth in the next few years. It will grow to $2.54 billion in 2029 at a compound annual growth rate (CAGR) of 12.2%. The growth during the forecast period is fueled by rising approvals of combination therapies with immuno-oncology, a growing pipeline of novel formulations and next-generation CDK inhibitors, expanded access to cancer treatment through government programs, increased biomarker-based patient selection, and longer therapy duration following positive overall survival outcomes. The primary trends in the forecast period include advancements in targeted therapy applications, integration of personalized medicine, expansion into emerging markets, innovation in formulation and delivery methods, and progress in clinical trial applications.
The rising incidence of breast cancer is expected to drive the growth of the abemaciclib market in the coming years. Breast cancer is a malignant tumor that originates in the breast tissue, mainly affecting the ducts or lobules, and has the potential to spread to other parts of the body if not treated. The increasing incidence of breast cancer is primarily due to enhanced detection and screening techniques, which allow for more diagnoses of cases that might have otherwise gone undetected. Abemaciclib helps manage breast cancer by inhibiting specific enzymes that promote tumor cell growth, thereby slowing disease progression and improving patient outcomes. For example, in February 2025, the International Agency for Research on Cancer (IARC), a France-based intergovernmental agency, reported that in 2022, approximately 2.3 million women were diagnosed with breast cancer globally, resulting in 670,000 deaths. Projections estimate 3.2 million cases and 1.1 million deaths annually by 2050. As a result, the increasing prevalence of breast cancer is driving the expansion of the abemaciclib market.
Companies operating in the abemaciclib market are focusing on innovations such as combination therapy with endocrine treatment to enhance treatment efficacy, reduce recurrence in high-risk early breast cancer patients, and expand therapeutic options across different stages of HR+, HER2- breast cancer. Combination therapy with endocrine treatment involves using abemaciclib alongside hormone-blocking therapy to more effectively slow or halt the growth of HR+ breast cancer cells. For instance, in November 2022, Eli Lilly and Company, a US-based pharmaceutical company, launched Ramiven in India to treat early-stage breast cancer. This therapy specifically targets patients with hormone receptor-positive (HR+), HER2-negative, node-positive tumors who are at high risk of recurrence. When used in combination with endocrine therapy, Ramiven improves treatment efficacy and reduces the likelihood of cancer returning. This launch significantly expands access to advanced, targeted therapies for high-risk breast cancer patients in India. The combination of abemaciclib with endocrine therapy aims to enhance patient outcomes and provide a more effective treatment strategy.
In February 2022, Veru Inc., a US-based biopharmaceutical company, collaborated with Eli Lilly and Company to advance the development and commercialization of targeted therapies focused on women's health and oncology. The partnership aims to assess the safety and effectiveness of combining Veru's enobosarm with Eli Lilly's Verzenio (abemaciclib) for second-line treatment of AR+ER+HER2 metastatic breast cancer. Eli Lilly and Company, which develops and provides abemaciclib, is working on providing more comprehensive treatment options for advanced and early breast cancer.
Major player in the in the abemaciclib market is Eli Lilly and Company.
North America was the largest region in the abemaciclib market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in abemaciclib report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the abemaciclib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The abemaciclib market consists of sales of dosage strength variants, clinical trial formulations, and combination kits or regimens. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Abemaciclib Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on abemaciclib market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for abemaciclib ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The abemaciclib market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product Type: Tablets; Capsules; Other Product Types
2) By Indication: Advanced Or Metastatic Breast Cancer; Early Breast Cancer; Other Indications
3) By Distribution Channel: Online; Offline
4) By End-User: Hospitals; Cancer Treatment Centers; Other End-Users
Subsegments:
1) By Tablets: Standard Tablets; Extended-Release Tablets
2) By Capsules: Hard Gelatin Capsules; Soft Gelatin Capsules
3) By Other Product Types: Oral Suspensions; Injectable Forms; Topical Forms
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Abemaciclib Market Characteristics
3. Abemaciclib Market Trends And Strategies
4. Abemaciclib Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Abemaciclib Growth Analysis And Strategic Analysis Framework
5.1. Global Abemaciclib PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Abemaciclib Market Growth Rate Analysis
5.4. Global Abemaciclib Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Abemaciclib Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Abemaciclib Total Addressable Market (TAM)
6. Abemaciclib Market Segmentation
6.1. Global Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablets
Capsules
Other Product Types
6.2. Global Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Advanced Or Metastatic Breast Cancer
Early Breast Cancer
Other Indications
6.3. Global Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Online
Offline
6.4. Global Abemaciclib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Cancer Treatment Centers
Other End-Users
6.5. Global Abemaciclib Market, Sub-Segmentation Of Tablets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Standard Tablets
Extended-Release Tablets
6.6. Global Abemaciclib Market, Sub-Segmentation Of Capsules, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hard Gelatin Capsules
Soft Gelatin Capsules
6.7. Global Abemaciclib Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Suspensions
Injectable Forms
Topical Forms
7. Abemaciclib Market Regional And Country Analysis
7.1. Global Abemaciclib Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Abemaciclib Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Abemaciclib Market
8.1. Asia-Pacific Abemaciclib Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Abemaciclib Market
9.1. China Abemaciclib Market Overview
9.2. China Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Abemaciclib Market
10.1. India Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Abemaciclib Market
11.1. Japan Abemaciclib Market Overview
11.2. Japan Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Abemaciclib Market
12.1. Australia Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Abemaciclib Market
13.1. Indonesia Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Abemaciclib Market
14.1. South Korea Abemaciclib Market Overview
14.2. South Korea Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Abemaciclib Market
15.1. Western Europe Abemaciclib Market Overview
15.2. Western Europe Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Abemaciclib Market
16.1. UK Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Abemaciclib Market
17.1. Germany Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Abemaciclib Market
18.1. France Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Abemaciclib Market
19.1. Italy Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Abemaciclib Market
20.1. Spain Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Abemaciclib Market
21.1. Eastern Europe Abemaciclib Market Overview
21.2. Eastern Europe Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Abemaciclib Market
22.1. Russia Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Abemaciclib Market
23.1. North America Abemaciclib Market Overview
23.2. North America Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Abemaciclib Market
24.1. USA Abemaciclib Market Overview
24.2. USA Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Abemaciclib Market
25.1. Canada Abemaciclib Market Overview
25.2. Canada Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Abemaciclib Market
26.1. South America Abemaciclib Market Overview
26.2. South America Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Abemaciclib Market
27.1. Brazil Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Abemaciclib Market
28.1. Middle East Abemaciclib Market Overview
28.2. Middle East Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Abemaciclib Market
29.1. Africa Abemaciclib Market Overview
29.2. Africa Abemaciclib Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Abemaciclib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Abemaciclib Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Abemaciclib Market Competitive Landscape And Company Profiles
30.1. Abemaciclib Market Competitive Landscape
30.2. Abemaciclib Market Company Profiles
30.2.1. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
31. Global Abemaciclib Market Competitive Benchmarking And Dashboard
32. Key Mergers And Acquisitions In The Abemaciclib Market
33. Recent Developments In The Abemaciclib Market
34. Abemaciclib Market High Potential Countries, Segments and Strategies
34.1 Abemaciclib Market In 2029 - Countries Offering Most New Opportunities
34.2 Abemaciclib Market In 2029 - Segments Offering Most New Opportunities
34.3 Abemaciclib Market In 2029 - Growth Strategies
34.3.1 Market Trend Based Strategies
34.3.2 Competitor Strategies
35. Appendix
35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer
(주)글로벌인포메이션02-2025-2992kr-info@giikorea.co.kr ⓒ Copyright Global Information, Inc. All rights reserved.
